These findings are in agreement with our observations in T2DM, where INS methylation showed a low capacity to discriminate T2DM, and GCK methylation revealed the best capacity, highlighting its potential clinical value as a minimally invasive biomarker for T2DM personalized management. This evidence concerns the gene GCK and type 2 diabetes mellitus.